Zacks Investment Research
20 Oct 2026, 22:51 UTC · 1h ago
Impact · against what's priced in
The article provides no new catalysts for RXRX, as the reported revenue and EPS projections are current consensus estimates already reflected in the stock's valuation. The overall outlook remains muted due to a projected 42.66% structural decline in full-year revenue.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Recursion Pharmaceuticals is expected to report quarterly revenue of $8.42 million, a 62.57% increase over the prior-year quarter.
Priced inanalysis of consensus estimates
So whatA beat on this $8.42M figure would signal accelerated commercialization of its AI-drug discovery platform ahead of the next print.
More positive than 81% of claims this week
Continue reading
5 related stories
The expected quarterly revenue of $8.42 million and EPS of -$0.24 are consensus estimates, and the 42.66% projected annual revenue decline is already known to the market.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The company's expected quarterly EPS of -$0.24 represents a 33.33% improvement over the prior-year quarter.
Priced inanalysis of consensus estimates
So whatNarrowing losses to -$0.24 per share suggests an improvement in operating efficiency for the current quarter.
More positive than 69% of claims this week
Full-year revenue estimates for RXRX are $42.82 million, representing a 42.66% decrease year-over-year.
Priced inanalysis of consensus estimates
So whatThe projected 42.66% annual revenue drop indicates a significant structural decline in top-line growth for FY2026.
More negative than 75% of claims this week
The Zacks Consensus EPS estimate for the company has shifted 0.72% downward over the past month.
Priced inanalysis of trends over the past month
So whatWhile small, the downward revision correlates with the stock's 9.07% price decline over the last 30 days.
More negative than 60% of claims this week
Which stocks this story touches
More positive than 58% of ticker scores this week
The stock outperformed the S&P 500 in the recent session and shows significant projected revenue growth, although it remains a 'Hold' with some negative monthly trends.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
—
RXRX hasn't traded since this ran. Last close $3.66 (Oct 20); the reaction starts at the next open.
RXRX chart →
